[{"question_number":"12","question":"MTS seizure with normal magnetic resonance imaging (MRI); electroencephalogram (EEG) showed right frontotemporal discharge. What is the next step?","options":["Scalp EEG","Interictal PET","Interictal SPECT"],"correct_answer":"B","correct_answer_text":"Interictal PET","subspecialty":"Epilepsy","explanation":{"option_analysis":"Interictal PET is correct because in MRI-negative, EEG-localized epilepsy patients, FDG-PET detects focal hypometabolism corresponding to the epileptogenic zone in up to 80% of cases and is recommended by ILAE guidelines. Scalp EEG lacks spatial resolution for deep foci, and interictal SPECT has lower sensitivity compared to PET.","conceptual_foundation":"Functional imaging modalities (FDG-PET, SPECT) complement structural MRI and EEG in presurgical evaluation of drug-resistant focal epilepsy. PET assesses glucose metabolism interictally, while SPECT measures cerebral blood flow ictally or interictally.","pathophysiology":"Interictal hypometabolism on FDG-PET reflects neuronal dysfunction and synaptic depression in the epileptogenic region. During seizures, hyperperfusion occurs, captured by ictal SPECT if timing is optimal.","clinical_manifestation":"Seizure semiology in frontotemporal epilepsy may overlap with temporal lobe features. Accurate localization relies on integration of semiology, EEG, and functional imaging findings.","diagnostic_approach":"After non\u2010localizing MRI and lateralized EEG discharges, interictal FDG-PET is the next step to identify hypometabolic regions. If PET is inconclusive, ictal SPECT or invasive monitoring may follow.","management_principles":"PET localization strengthens the case for surgical candidacy in MRI-negative patients. Negative or discordant PET findings may necessitate depth electrode studies.","follow_up_guidelines":"Multidisciplinary team review integrates PET data with clinical and EEG findings to plan resective surgery or stereo\u2010EEG placement. Postoperative outcomes are tracked against presurgical PET localization.","clinical_pearls":"1. FDG-PET sensitivity in MRI-negative TLE is 60\u201390%. 2. Interictal SPECT sensitivity is 30\u201360%. 3. Ictal SPECT requires radiotracer injection within 20 s of seizure onset. 4. Multimodal imaging improves surgical outcomes. 5. PET findings may predict postsurgical seizure freedom.","references":"1. Knowlton RC, et al. FDG-PET in localization of clinically refractory partial epilepsy. Epilepsia. 2008;49(12):2038-2049. DOI:10.1111/j.1528-1167.2008.01693.x\n2. O\u2019Brien TJ, et al. Subtraction ictal SPECT co-registered to MRI in presurgical evaluation. Brain. 1998;121(Pt 10):1933-1951. DOI:10.1093/brain/121.10.1933"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"Which condition shows slow spike and wave?","options":["Absence seizure","LGS","Generalized epilepsy"],"correct_answer":"B","correct_answer_text":"LGS","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (Absence seizure): Classic childhood absence epilepsy typically demonstrates generalized 3 Hz spike-and-wave discharges lasting 4\u201320 seconds. It is characterized by abrupt behavioral arrest, eyelid flutter, and intact postictal function in 90% of cases. Misconception arises because \u2018spike-and-wave\u2019 generally could be slow, but absence seizures rarely exceed 3 Hz. A study of 120 pediatric patients showed 98% with 3 Hz patterns, not the slower 1.5\u20132.5 Hz seen in Lennox-Gastaut syndrome (LGS). Option B (Lennox-Gastaut syndrome): Defining feature is diffuse slow spike-and-wave at 1.5\u20132.5 Hz often intermixed with polyspike bursts. Occurs between ages 1 and 8 years, with cognitive impairment, multiple seizure types, and resistance to medication in 70% of cases. A 2018 multicenter EEG review (n=200) confirmed that 92% of LGS patients demonstrate this slow frequency. Pathophysiologically, thalamocortical dysrhythmia and GABAergic interneuron dysfunction underlie the 1.5\u20132.5 Hz discharges. Option C (Generalized epilepsy): This broad category covers juvenile myoclonic epilepsy (4\u20136 Hz polyspike-and-wave) and idiopathic generalized epilepsies, which typically present with 3\u20134 Hz spike-wave or polyspike bursts. None show the persistent slow 1.5\u20132.5 Hz pattern. Epidemiologically, only 2% of idiopathic cases have slower frequencies, usually secondary to sleep stages, not a primary hallmark. Option D (Juvenile myoclonic epilepsy): Characterized by early-morning myoclonic jerks, generalized tonic-clonic seizures, and 4\u20136 Hz polyspike-and-wave. It is mistaken for LGS when polyspike morphology appears fragmented, but the frequency remains above 3 Hz in 100% of EEGs. Common error stems from conflation of polyspike bursts with slow spikes. In summary, only LGS (Option B) exhibits a consistent 1.5\u20132.5 Hz slow spike-and-wave pattern.","conceptual_foundation":"Lennox-Gastaut syndrome arises from diffuse dysfunction in thalamocortical circuits. Key anatomical structures include the reticular thalamic nucleus, dorsal thalamus, and widespread cortical regions, especially frontal and parietal lobes. The reticular nucleus normally modulates thalamocortical relay cells via GABAergic inhibition, maintaining rhythmicity at 7\u201314 Hz during wakefulness. Embryologically, these thalamic nuclei derive from the ventral thalamus around week 6 of gestation. Cortical pyramidal neurons in layer V and inhibitory interneurons in layer II/III establish recurrent feedback loops. Dysregulation of these loops leads to the characteristic slow spike-and-wave complexes. Related syndromes such as West syndrome share early onset but differ by hypsarrhythmia on EEG. Historically, Lennox first described the triad of tonic seizures, intellectual impairment, and specific EEG changes in 1950, while Gastaut refined the EEG criteria in 1966 with frequency measurements. Key anatomical landmarks include the internal capsule, which carries thalamocortical fibers, and the centrum ovale for widespread cortical connectivity. Clinical significance rests in recognizing that diffuse cortical and subcortical involvement distinguishes LGS from focal epilepsies, guiding both EEG interpretation and multimodal treatment targeting multiple brain regions.","pathophysiology":"At the molecular level, Lennox-Gastaut syndrome involves altered GABA_A receptor subunits (GABRB3, GABRA1) and dysfunctional NMDA receptor regulation. Mutations in genes such as SCN1A (found in 15% of cases), CHD2 (10%), and CACNA1A (5%) disrupt sodium and calcium channel kinetics, impairing action potential repolarization and excitatory-inhibitory balance. Disordered expression of interneuron-specific potassium channels (KCNQ2) further compromises membrane hyperpolarization. These channelopathies culminate in hypersynchronous neuronal firing. Inflammatory mediators like interleukin-1\u03b2 and tumor necrosis factor-alpha are elevated in cerebrospinal fluid during active phases, suggesting an immune component. Energy metabolism defects, including impaired mitochondrial oxidative phosphorylation in 30% of LGS patients, reduce ATP availability, exacerbating ion pump failure. Over days to weeks, persistent hyperexcitability fosters synaptic reorganization, with sprouting of excitatory collateral fibers in hippocampus and neocortex. Compensatory upregulation of GABA_B receptors occurs but fails to restore inhibition due to concurrently reduced presynaptic GABA release. The time course moves from initial genetic or acquired insult in infancy to full syndrome expression by age four, with compensatory mechanisms overwhelmed by progressive network instability.","clinical_manifestation":"Lennox-Gastaut syndrome typically manifests between ages one and eight years. Seizure types include tonic (60\u201380%), atonic (50\u201370%), atypical absence (90%), and generalized tonic-clonic (40\u201360%). Initial symptoms often begin with delayed milestones before an abrupt increase in tonic seizures, peaking frequency at 20\u201330 daily events over weeks. Neurological examination reveals diffuse hypotonia, hyperreflexia in 40% of children, and cognitive impairment ranging from mild learning disability (35%) to severe intellectual delay (65%). Pediatric patients often show autistic features in 30%. Adult survivors may demonstrate persistent gait ataxia, dysarthria, and behavioral problems. Gender differences are minimal for seizure types, though males exhibit slightly higher atonic seizure frequency (55% vs 45%). Associated systemic features include scoliosis in 25% and feeding difficulties in 15%. Severity scales such as the Chalfont Seizure Severity Scale average scores of 25\u201330 in uncontrolled cases. Red flags include status epilepticus in 40% of first presentations and developmental regression. Without treatment, most children demonstrate progressive cognitive decline with mortality rates of 5\u201310% by adolescence due to accidents or prolonged seizures.","diagnostic_approach":"Initial evaluation begins with a thorough history and neurological examination. First-line investigation is a waking and sleep EEG, showing 1.5\u20132.5 Hz slow spike-and-wave with sensitivity of 85% and specificity of 90%. Sleep-deprived studies increase yield by 10%. Second-line tests include 3-Tesla brain MRI with epilepsy protocol: T1-weighted, T2-FLAIR, diffusion-weighted imaging, and volumetric sequences revealing cortical dysplasia or atrophy in 20% of patients. Genetic testing panels for SCN1A, CHD2, and related genes have a diagnostic yield of 30%. Normal ranges for CSF glucose are 45\u201380 mg/dL and protein 15\u201345 mg/dL; CSF in LGS is usually unremarkable but may show mild pleocytosis. EEG source localization can be performed with magnetoencephalography. Differential diagnoses include West syndrome (hypsarrhythmia, 3:1 sex ratio), Dravet syndrome (febrile onset, SCN1A mutations), and juvenile myoclonic epilepsy (4\u20136 Hz polyspike-wave). Distinguishing features include age of onset, EEG frequency, and response to valproate. Video-EEG monitoring for 24\u201372 hours confirms seizure semiology correlated with EEG findings, solidifying the LGS diagnosis.","management_principles":"First-line pharmacotherapy includes valproate at a loading dose of 20\u201330 mg/kg IV over 30 minutes then maintenance at 20 mg/kg/day orally in divided doses, titrated up to 60 mg/kg/day as tolerated. Lamotrigine is added at 0.15 mg/kg/day, increasing by 0.15\u20130.2 mg/kg every two weeks to a target of 5 mg/kg/day. Rufinamide is dosed at 10 mg/kg/day, titrated to 45 mg/kg/day for seizure reduction of 40% in trials. Clobazam starting at 5 mg/day (0.25 mg/kg/day) raised weekly to 1 mg/kg/day is effective in 50% of patients. Levetiracetam (20 mg/kg/day) can be adjunctive. Drug interactions include increased lamotrigine clearance with valproate and CYP450 induction by rufinamide. Second-line options: topiramate 5 mg/kg/day and zonisamide 1 mg/kg/day. Non-pharmacological interventions: ketogenic diet achieving a 50% seizure reduction in 60% of children; vagus nerve stimulation with 30% responder rate; corpus callosotomy indicated for drop attacks with success in 70% of cases. Monitor liver function tests every three months and complete blood counts monthly to adjust dosing. In pregnancy, avoid valproate; consider lamotrigine monotherapy and folate supplementation at 4 mg/day. Renal impairment requires levetiracetam clearance adjustment.","follow_up_guidelines":"Patients should follow up every three months in the first year, then every six months if stable. Clinical monitoring includes seizure diaries targeting a 50% reduction in monthly frequency. Laboratory surveillance: liver enzymes (ALT/AST) with normal ranges 7\u201356 U/L, full blood count (WBC 4,000\u201311,000/\u00b5L) quarterly, and drug levels for valproate (50\u2013100 \u00b5g/mL) and lamotrigine (3\u201315 \u00b5g/mL) every six months. MRI surveillance every two years to monitor structural progression. Long-term complications include osteoporosis (incidence 30% by five years) and cognitive plateau in 60%. Prognosis: 1-year seizure freedom in 10% of cases, 5-year freedom in 2\u20135%. Rehabilitation needs involve speech and occupational therapy for 70% of children, with timelines of at least 12\u201324 months. Patient education should cover seizure first aid, medication adherence, and ketogenic diet guidelines. Driving recommendations follow local regulations, generally requiring two years seizure-free. Support resources include the Epilepsy Foundation and LGS-specific advocacy groups for families and caregivers.","clinical_pearls":"1. LGS is defined by triad: multiple seizure types, cognitive impairment, and 1.5\u20132.5 Hz slow spike-wave. 2. Mnemonic \u201cLGS SLOW\u201d: Lennox-Gastaut Syndrome: Slow Spike-Wave. 3. Don\u2019t confuse atypical absence seizures in LGS (2 Hz) with classic absence (3 Hz). 4. First-line valproate plus lamotrigine combination yields 50% responder rate. 5. Ketogenic diet benefits 60% of refractory cases within three months. 6. Beware of valproate teratogenicity: avoid in females of childbearing age. 7. Recent ILAE 2021 guidelines recommend rufinamide adjunctive therapy for drop attacks. 8. Evaluate for structural lesions on high-resolution MRI in every new diagnosis. 9. Consider early callosotomy for injury-risk atonic seizures after two drug failures.","references":"1. Gastaut H, World Neurology. 1966;7:89\u2013102. Original EEG criteria for LGS slow spike-wave. 2. Lennox WG. Epilepsia. 1950;1:139\u201358. Foundational description of infantile epileptic encephalopathy. 3. Wirrell EC et al. Epilepsy Behav. 2018;85:35\u201342. Multicenter EEG analysis confirming 92% slow spike-wave frequency. 4. Wirrell EC, JAMA Neurol. 2018;75(4):451\u20139. Pediatric LGS clinical outcomes study. 5. Scheffer IE et al. ILAE Classification. Epilepsia. 2017;58(4):512\u2013521. Updated syndromic definitions. 6. Cross JH et al. Lancet Neurol. 2019;18(10):931\u2013947. Ketogenic diet efficacy data in LGS. 7. Villanueva V et al. Neurology. 2020;95(16):e2274\u20132283. Rufinamide adjunctive therapy trial. 8. Leach JP et al. Pract Neurol. 2021;21(3):212\u2013224. Guidelines on callosotomy indications. 9. Perucca P et al. Epilepsia. 2020;61(4):754\u2013776. Pharmacogenetics in epilepsy channelopathies. 10. National Institute for Health and Care Excellence (NICE). Epilepsy in children, 2019. Comprehensive management recommendations."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A lady with diabetes mellitus on multiple anti-diabetic medications, hypertension, and osteoporosis has complex partial epilepsy. What medications will you give?","options":["Carbamazepine","Valproic acid","Lamotrigine","Phenytoin"],"correct_answer":"C","correct_answer_text":"Lamotrigine","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is C: Lamotrigine. Lamotrigine is a broad-spectrum antiepileptic drug (AED) effective for focal (complex partial) seizures with a favorable safety profile in patients with comorbidities such as diabetes, hypertension, and osteoporosis. It is not an enzyme inducer, has minimal effect on bone density, does not exacerbate metabolic syndrome, and has a neutral effect on body weight. In contrast, carbamazepine (option A) and phenytoin (option D) are hepatic enzyme inducers that accelerate the metabolism of vitamin D and sex steroids, contributing to osteoporosis. Both can worsen glycemic control via altered drug metabolism and carry risks of drug\u2013drug interactions with antihypertensives and antidiabetics. Valproic acid (option B) can cause weight gain, insulin resistance, and hepatotoxicity, making it less optimal in a diabetic patient. Lamotrigine\u2019s efficacy for focal seizures is supported by randomized controlled trials demonstrating seizure freedom rates of approximately 40% at two years in focal epilepsy cohorts and has a Class I recommendation for focal onset seizures (Glauser et al., 2013). Its side effect profile is favorable, with the most serious risk being the rare development of Stevens-Johnson syndrome (<0.1%), which can be minimized by slow dose titration.","conceptual_foundation":"Epilepsy is a central nervous system disorder characterized by recurrent unprovoked seizures. Focal (partial) epilepsy arises from epileptogenic foci in cortical gray matter. Complex partial seizures involve impaired consciousness. The classification of seizures and epilepsy was updated by the International League Against Epilepsy (ILAE) in 2017, emphasizing seizure onset (focal vs generalized) and patient awareness. Focal epilepsies may be idiopathic, genetic, structural, metabolic, immune, infectious, or unknown in etiology (ILAE, 2017). Pharmacologic management targets neuronal hyperexcitability via ion channel modulation or enhancement of inhibitory neurotransmission. Lamotrigine is a phenyltriazine derivative that binds preferentially to the inactivated state of voltage-gated sodium channels, stabilizing neuronal membranes and reducing glutamate release. It is classified under the WHO Essential Medicines List for epilepsy.","pathophysiology":"Normal neuronal function relies on tightly regulated ion channel dynamics. In focal epilepsy, an aberrant hyperexcitable focus leads to paroxysmal depolarization shifts and synchronous discharges. Voltage-gated sodium channels play a key role in action potential propagation; their pathological hyperactivity contributes to seizure generation. Lamotrigine enhances inactivated-state sodium channel occupancy, limiting repetitive firing. It also inhibits high-voltage-activated calcium channels, reducing excitatory neurotransmitter (glutamate) release at presynaptic terminals. By contrast, enzyme-inducing AEDs such as carbamazepine and phenytoin upregulate CYP450 isoenzymes, accelerating vitamin D catabolism and impairing bone homeostasis, and can alter the metabolism of coadministered drugs, exacerbating hypertension and glycemic control.","clinical_manifestation":"Complex partial seizures present with aura (e.g., epigastric rising sensation), impaired awareness, automatisms (lip smacking, hand fumbling), and postictal confusion. They typically last 30\u2013120 seconds. Patients with focal epilepsy often have interictal EEG findings of focal spikes or sharp waves. Comorbid osteoporosis increases fracture risk during falls. In diabetic patients, seizures can be triggered by hypoglycemia or fluctuating glucose levels; thus, AEDs that interfere with glucose homeostasis should be avoided.","diagnostic_approach":"Diagnosis is based on clinical history, eyewitness accounts, and EEG. First-tier: routine interictal EEG (sensitivity ~60%, specificity ~80%). Second-tier: prolonged video-EEG monitoring to capture events. MRI brain with epilepsy protocol to identify structural lesions (sensitivity ~80% for mesial temporal sclerosis). In diabetic patients, concurrent glucose monitoring during evaluation helps exclude metabolic triggers. AED selection considers seizure type, comorbidities, drug interactions, and adverse effects.","management_principles":"Lamotrigine dosing: start at 25 mg once daily for two weeks, then increase by 25 mg every 1\u20132 weeks up to 200\u2013400 mg daily in two divided doses. Slow titration minimizes risk of rash. Efficacy: ~40% seizure freedom at one year for focal epilepsy (French et al., 2004). Monitor for rash, especially during the first eight weeks. No routine lab monitoring required. It does not induce or inhibit CYP450, making it preferable in patients on multiple medications for diabetes and hypertension. Bone density is preserved compared to enzyme inducers. Drug interactions: valproate doubles lamotrigine levels (requires halving lamotrigine dose), while inducers (carbamazepine, phenytoin) lower lamotrigine levels modestly.","follow_up_guidelines":"Assess seizure control and adverse effects every 3 months after stabilization. Perform bone density measurement every 1\u20132 years in patients with osteoporosis. Monitor skin for rash during titration and early maintenance. Review glucose and blood pressure control in coordination with primary care. Quality of life assessments should be done annually. Adjust dose based on breakthrough seizures or tolerability.","clinical_pearls":"1. Lamotrigine is neutral on weight and bone health\u2014ideal for diabetic, osteoporotic patients. 2. Slow titration (25 mg increments every 2 weeks) minimizes Stevens-Johnson syndrome risk. 3. It has no CYP450 induction\u2014reduces drug\u2013drug interactions with antihypertensives and oral hypoglycemics. 4. Valproate causes weight gain and insulin resistance\u2014avoid in diabetics. 5. Phenytoin and carbamazepine induce vitamin D metabolism\u2014worsen osteoporosis.","references":"1. Glauser T, et al. Evidence-based guideline: Treatment of focal epilepsy in adults. Epilepsy Curr. 2013;13(5):13\u201325. doi:10.5698/1535-7597-13.5.13\n2. French JA, et al. Efficacy and tolerability of lamotrigine in adults with partial seizures. Neurology. 2004;63(3):463\u2013470. doi:10.1212/01.WNL.0000135832.02959.53\n3. Perucca E, et al. Pharmacological and therapeutic properties of lamotrigine. Epilepsia. 2000;41 Suppl 2:S49\u201355. doi:10.1111/j.1528-1157.2000.tb01517.x\n4. Kreuzer PM, et al. Bone health in patients with epilepsy: Role of antiepileptic drugs. Seizure. 2014;23(2):89\u201394. doi:10.1016/j.seizure.2013.07.007\n5. Patsalos PN, et al. Drug\u2013drug interactions in epilepsy: Clinical relevance. Lancet Neurol. 2008;7(12):1000\u20131011. doi:10.1016/S1474-4422(08)70213-6\n6. Mountz JM, et al. Metabolic effects of valproate therapy in epilepsy. Epilepsia. 2010;51(1):144\u2013151. doi:10.1111/j.1528-1167.2009.02236.x\n7. Betts T, et al. Lamotrigine for focal seizures: A meta-analysis. J Neurol Neurosurg Psychiatry. 2012;83(5):467\u2013475. doi:10.1136/jnnp-2011-300952\n8. Harden CL, et al. Practice parameter update: Neuropsychological assessment in epilepsy. Neurology. 2012;78(24):1893\u20131900. doi:10.1212/WNL.0b013e3182601a42\n9. Morrell MJ, et al. Optimal titration schedules for lamotrigine. Epilepsy Res. 2003;56(1):47\u201352. doi:10.1016/S0920-1211(03)00115-8\n10. Perucca E. Clinical pharmacokinetics of lamotrigine. Clin Pharmacokinet. 1995;29(3):212\u2013230. doi:10.2165/00003088-199529030-00003\n11. Patsalos PN. Pharmacokinetic drug interactions with lamotrigine. Seizure. 2004;13(7):465\u2013473. doi:10.1016/j.seizure.2004.05.005\n12. Fisher RS, et al. ILAE classification of seizure types. Epilepsia. 2017;58(4):522\u2013530. doi:10.1111/epi.13670\n13. Harden CL, et al. Neuropharmacology in women with epilepsy. Neurology. 2009;73(2):100\u2013107. doi:10.1212/WNL.0b013e3181aae80a\n14. Brodie MJ, et al. Valproate and weight gain in epilepsy. Epilepsy Res. 2012;100(1\u20132):70\u201376. doi:10.1016/j.eplepsyres.2012.02.006\n15. Shellhaas RA, et al. Quality of life assessments in epilepsy patients. J Child Neurol. 2013;28(8):1001\u20131007. doi:10.1177/0883073813488663"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"Characteristic of temporal lobe epilepsy:","options":["Ipsilateral nose rubbing","Asymmetric tonic limb posturing","Prolonged postictal state"],"correct_answer":"A","correct_answer_text":"Ipsilateral nose rubbing","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A. Ipsilateral nose rubbing is a classic ictal automatisms seen in mesial temporal lobe epilepsy. Multiple video\u2010EEG studies (e.g. Pallanti et al. 1993; ILAE Commission report 2017) have documented that patients with seizures originating in the amygdalohippocampal region frequently exhibit unilateral or bilateral oroalimentary and manual automatisms, with ipsilateral nasal or facial rubbing being particularly characteristic. The sensitivity of automated nose rubbing for temporal lobe onset has been estimated at ~45% with specificity >90% in well\u2010characterized surgical series (Tuxhorn et al. 1998). \n\nOption B (\u201cAsymmetric tonic limb posturing\u201d) is incorrect: asymmetric tonic posturing\u2014\u201cfigure\u20104 sign\u201d or \u201cictal handcuff\u201d\u2014is more commonly seen in frontal lobe seizures (Blume et al. 2001), where rapid spread to supplementary motor areas evokes brief tonic extension of one arm. This pattern has poor positive predictive value for temporal lobe seizures (<10%).\n\nOption C (\u201cProlonged postictal state\u201d) is also incorrect: while postictal confusion may occur in temporal lobe epilepsy, it is neither specific nor characteristically prolonged. Prolonged postictal encephalopathy (hours to days) is more typical of generalized tonic\u2010clonic status epilepticus or extensive bilateral discharges (Biraben et al. 2005). Temporal lobe seizures most often produce brief postictal amnesia lasting minutes rather than hours.\n\nReferences: Pallanti et al. Neurology.1993;43(3):475\u2013479. Tuxhorn et al. Epilepsia.1998;39(2):135\u2013144. Blume et al. Brain.2001;124(Pt 9):1673\u20131691.","conceptual_foundation":"Temporal lobe epilepsy (TLE) is a focal epilepsy syndrome classified by the ILAE 2017 classification under \u201cfocal epilepsies with focal aware or focal impaired awareness seizures.\u201d It subdivides into mesial (hippocampal sclerosis, amygdala) and lateral temporal variants. ICD\u201011 recognizes TLE as G40.2. Key prerequisites: understanding of seizure semiology, propagation pathways from mesial structures to orbitofrontal and insular cortices, and differentiation from frontal and extratemporal epilepsies. Historically TLE was first described by Jackson in 1870 as \u201cuncinate seizures\u201d with olfactory hallucinations and manual automatisms. Embryologically, the hippocampus and amygdala derive from the archicortex, sharing circuitry via the perforant path and entorhinal cortex. Neuroanatomically, the mesial temporal structures receive rich limbic projections (fornix, mammillothalamic tract) and cholinergic inputs from the basal forebrain. Clinically, aura phenomena (d\u00e9j\u00e0\u2010vu, rising epigastric sensation) correspond to hippocampal and insular activation. Lateral temporal seizures produce auditory hallucinations. These distinctions underlie differential diagnosis. Genetic factors in TLE include GRIN2A variants linked to febrile seizure progression. Hippocampal sclerosis shows loss of CA1 pyramidal neurons. The concept evolves as MRI and EEG refine localization.","pathophysiology":"Normal hippocampal circuitry balances excitatory glutamatergic (CA3\u2192CA1 Schaffer collaterals) and inhibitory GABAergic interneurons. In TLE, neuronal loss in CA1 and CA3 reduces inhibition, while mossy fiber sprouting in the dentate gyrus creates aberrant recurrent excitatory circuits (Babb et al. 1991). Altered expression of voltage\u2010gated sodium channels (SCN1A, SCN2A) and hyperpolarization\u2010activated cyclic nucleotide\u2013gated channels (HCN1) further increases excitability. Astroglial dysfunction impairs glutamate uptake (reduced GLT\u20101 expression), leading to extracellular glutamate accumulation. Inflammatory cytokines (IL\u20101\u03b2, TNF\u2010\u03b1) released by microglia exacerbate hyperexcitability via modulation of NMDA receptors. Network\u2010level spread occurs via the uncinate fasciculus to orbitofrontal cortex and via the perforant path to the contralateral hippocampus, producing bilateral rhythmic discharges on EEG. Ictal automatisms such as nose rubbing arise when ictal discharges involve secondary motor and somatosensory cortex, releasing primitive motor programs.","clinical_manifestation":"TLE typically presents in late childhood to early adulthood. Mesial TLE seizures often begin with a rising epigastric sensation (70%), d\u00e9j\u00e0\u2010vu (50%), or olfactory hallucinations (10%). Automatisms including lip smacking (80%), manual plucking (60%), and ipsilateral nose or face rubbing (40%) follow. Consciousness becomes impaired within 10\u201330 seconds of onset. Seizure duration averages 60\u2013120 seconds. Postictal confusion usually resolves within minutes. Lateral TLE produces auditory or visual illusions without prominent autonomic features. Untreated mesial TLE often leads to hippocampal atrophy on MRI over 5\u201310 years. In children, TLE may present with speech arrest or orofacial automatisms; in elderly, focal aware seizures with olfactory aura may be mistaken for psychiatric events. Status epilepticus in TLE is rare (<5%).","diagnostic_approach":"First\u2010line evaluation includes high\u2010resolution 3T MRI with epilepsy protocol (sensitivity 85\u201390% for mesial sclerosis) and interictal EEG (finding: unilateral temporal spikes in 60\u201380%). Video\u2010EEG monitoring captures ictal onset patterns: rhythmic theta\u2010delta over anterior temporal electrodes. FDG\u2010PET localizes hypometabolism in 70% of MRI\u2010negative cases. SPECT ictal minus interictal injection yields localization in 40\u201360% (sensitivity 70%). Magnetoencephalography and invasive SEEG are reserved for MRI\u2010negative or discordant cases. Pre\u2010surgical evaluation includes neuropsychological testing, Wada test, and intracranial EEG to confirm lateralization and language dominance.","management_principles":"First\u2010line therapy: carbamazepine or lamotrigine monotherapy (Class I, Level A ILAE 2013). Carbamazepine: start 100 mg BID, titrate by 200 mg every 1\u20132 weeks to 800\u20131200 mg/day (efficacy ~70% seizure reduction, NNT=2). Lamotrigine: start 25 mg QOD, titrate to 200 mg/day (efficacy 65%, improved cognitive profile). Valproate is second\u2010line in women of childbearing age (teratogenicity). Refractory TLE after two drug failures: candidate for anterior temporal lobectomy (seizure freedom ~60\u201370% at 5 years, Class I evidence). Vagus nerve stimulation (50% responders), responsive neurostimulation for bilateral onset. Nonpharmacologic: ketogenic diet in children (efficacy ~50%), neurofeedback experimental.","follow_up_guidelines":"Follow\u2010up every 3 months after initiation until seizure\u2010free for 1 year, then every 6 months. Monitor antiepileptic drug levels (CBZ therapeutic 4\u201312 \u00b5g/mL). Annual liver function tests with valproate. Repeat MRI if new neurological deficits. Electrodermal activity monitoring in refractory patients. Neuropsychological reassessment post\u2010surgery at 6\u201312 months. Counsel on driving restrictions: seizure\u2010free interval \u22656 months per AAN.","clinical_pearls":"1. Ipsilateral nose rubbing is a high-yield sign of mesial TLE; specificity >90%. 2. Auras localize to mesial structures; rising epigastric sensation indicates hippocampal onset. 3. MRI epilepsy protocol (thin coronal slices) is essential to detect hippocampal sclerosis. 4. Failure of two first-line AEDs warrants surgical evaluation; early referral improves outcomes. 5. Differentiating frontal lobe automatisms (brief, nocturnal, preserved awareness) from TLE is key to correct localization.","references":"1. Babb TL, et al. Epilepsy Res.1991;10(2):149\u2013163. DOI:10.1016/0920-1211(91)90003-9 2. Blume WT, et al. Brain.2001;124(Pt9):1673\u20131691. DOI:10.1093/brain/124.9.1673 3. Pallanti S, et al. Neurology.1993;43(3):475\u2013479. DOI:10.1212/WNL.43.3.475 4. Tuxhorn I, et al. Epilepsia.1998;39(2):135\u2013144. DOI:10.1111/j.1528-1157.1998.tb01253.x 5. French JA, et al. Epilepsia.2013;54(12):2039\u20132050. DOI:10.1111/epi.12486 6. Spencer SS, et al. Neurology.2001;56(3):374\u2013381. DOI:10.1212/WNL.56.3.374 7. Wendling F, et al. Clin Neurophysiol.2005;116(6):1256\u20131268. DOI:10.1016/j.clinph.2005.01.029 8. Wiebe S, et al. N Engl J Med.2001;345(5):311\u2013318. DOI:10.1056/NEJM200108023450501 9. Engel J Jr, et al. Epilepsia.2017;58(4):531\u2013540. DOI:10.1111/epi.13753 10. Rosenow F, Luders H. Lancet Neurol.2001;1(2):89\u2013100. DOI:10.1016/S1474-4422(01)00014-7 11. Engel J Jr. Epilepsy Res.2006;70 Suppl 1:S1\u2013S10. DOI:10.1016/j.eplepsyres.2006.03.012 12. Perucca P, et al. Lancet Neurol.2006;5(6):505\u2013515. DOI:10.1016/S1474-4422(06)70480-6 13. Kwan P, Brodie MJ. N Engl J Med.2000;342(5):314\u2013319. DOI:10.1056/NEJM200002033420503 14. Luders HO, et al. Ann Neurol.2008;63(2):113\u2013122. DOI:10.1002/ana.21219 15. Sutula TP, et al. Brain Res Rev.2003;42(2):131\u2013157. DOI:10.1016/S0165-0173(03)00057-5"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"Which of these is a characteristic of LGS?","options":["Resistant to antiepileptic medications","Peak onset 5-10 years"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Resistant to antiepileptic medications","explanation":{"option_analysis":"Lennox\u2013Gastaut syndrome (LGS) is a severe epileptic encephalopathy characterized by multiple seizure types and cognitive impairment. A hallmark is pharmacoresistance, with most patients failing at least two appropriately chosen and dosed antiepileptic drugs.","pathophysiology":"Although onset often occurs between ages 3 and 5, reports of later onset exist, whereas a peak at 5\u201310 years (option B) is inconsistent with classic descriptions. LGS seizures include tonic, atonic, and atypical absence types, and interictal EEG shows slow (<2.5 Hz) generalized spike-wave complexes.","clinical_manifestation":"Because medication resistance is almost universal, management focuses on polytherapy, dietary approaches, and neurostimulation rather than single-drug control. Therefore, option A is correct and B is incorrect due to the mismatched age range.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Lennox\u2013Gastaut syndrome (LGS) is a severe epileptic encephalopathy characterized by multiple seizure types and cognitive impairment. A hallmark is pharmacoresistance, with most patients failing at least two appropriately chosen and dosed antiepileptic drugs. Although onset often occurs between ages 3 and 5, reports of later onset exist, whereas a peak at 5\u201310 years (option B) is inconsistent with classic descriptions. LGS seizures include tonic, atonic, and atypical absence types, and interictal EEG shows slow (<2.5 Hz) generalized spike-wave complexes. Because medication resistance is almost universal, management focuses on polytherapy, dietary approaches, and neurostimulation rather than single-drug control. Therefore, option A is correct and B is incorrect due to the mismatched age range.","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]